Investigational Drug Information for Rivoglitazone
What is the development status for investigational drug Rivoglitazone?
Rivoglitazone is an investigational drug.
There have been 5 clinical trials for Rivoglitazone.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 14th 2007.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and [disabled in preview]. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo, Inc., and Daiichi Sankyo Co., Ltd.
Summary for Rivoglitazone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,977 |
| WIPO Patent Applications | 752 |
| Japanese Patent Applications | 248 |
| Clinical Trial Progress | Phase 3 (2007-11-14) |
| Vendors | 25 |
Recent Clinical Trials for Rivoglitazone
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus | Daiichi Sankyo Inc. | Phase 3 |
| Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus | Daiichi Sankyo, Inc. | Phase 3 |
| Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes | Daiichi Sankyo Co., Ltd. | Phase 2 |
Clinical Trial Summary for Rivoglitazone
Top disease conditions for Rivoglitazone
Top clinical trial sponsors for Rivoglitazone
US Patents for Rivoglitazone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Rivoglitazone Development Update and Market Projection
Rivoglitazone, also known as CS-011, is an investigational thiazolidinedione and selective peroxisome proliferator-activated receptor gamma, or PPAR-gamma, agonist developed for type 2 diabetes. Public development records indicate that the program reached mid- to late-stage clinical development but did not progress to regulatory approval. Rivoglitazone is not marketed, is not listed as an FDA-approved drug, and has no established commercial revenue base.
The commercial outlook is therefore limited unless the compound is revived for a differentiated metabolic indication, reformulated to reduce class-related safety concerns, or licensed to a company willing to conduct new clinical development.
What is the current development status of rivoglitazone?
Rivoglitazone appears to be a discontinued or inactive development program rather than an active late-stage asset.
| Attribute | Rivoglitazone status |
|---|---|
| Active ingredient | Rivoglitazone |
| Development code | CS-011 |
| Drug class | Thiazolidinedione; PPAR-gamma agonist |
| Primary indication | Type 2 diabetes |
| Historical developer | Daiichi Sankyo and predecessor organizations |
| Regulatory status | Not approved by the FDA, EMA, or Japan’s PMDA based on publicly available regulatory records |
| Clinical status | Historical Phase 2 and Phase 3 development reported; no current active commercial program identified |
| Commercial status | Not marketed |
| Orange Book status | No FDA Orange Book listing identified |
| Generic status | No approved generic pathway because no reference product has been approved |
| Biosimilar relevance | Not applicable; rivoglitazone is a small molecule |
Clinical development focused on improving insulin sensitivity and glycemic control through PPAR-gamma activation. The mechanism is established within the thiazolidinedione class, which includes pioglitazone and rosiglitazone. Rivoglitazone did not achieve the regulatory or commercial position of those marketed products.
What clinical development did rivoglitazone complete?
Public clinical-trial records and historical pipeline disclosures place rivoglitazone in clinical development for type 2 diabetes. The program included studies assessing glycemic control, insulin sensitivity, safety, and tolerability in patients with diabetes.
The available record supports the following development profile:
| Development element | Publicly reported position |
|---|---|
| Preclinical pharmacology | PPAR-gamma agonist activity and insulin-sensitizing effects |
| Early clinical work | Completed |
| Mid-stage studies | Conducted in patients with type 2 diabetes |
| Late-stage development | Reported in historical pipeline materials |
| New-drug application | No public approval identified |
| Current clinical recruitment | No active commercial-stage recruitment identified |
| Development continuity | No evidence of a current Phase 3 or registration program |
The central development challenge was the risk-benefit profile of the PPAR-gamma class. Thiazolidinediones can improve insulin sensitivity but may cause weight gain, edema, fluid retention, heart-failure risk, fractures, and other tolerability concerns. These risks have increased the clinical and regulatory burden for newer drugs in the class.
Rivoglitazone would need to demonstrate a material safety or efficacy advantage over generic pioglitazone to justify renewed development. A modest improvement in hemoglobin A1c alone would probably not support a new global registration program.
Is rivoglitazone approved by the FDA or listed in the Orange Book?
No. Rivoglitazone is not an FDA-approved active ingredient and does not have an FDA Orange Book reference product.
That status has several consequences:
- There is no FDA-approved rivoglitazone label.
- There is no reference-listed drug for an abbreviated new drug application.
- There is no conventional Paragraph IV challenge pathway against a rivoglitazone reference product.
- There is no FDA-listed five-year new chemical entity exclusivity period.
- There is no approved product generating U.S. prescription revenue.
The same issue applies to biosimilar analysis. Rivoglitazone is a chemically synthesized small molecule, not a biologic. Any future competitor would be evaluated through the generic-drug framework after approval of a reference product, not through the biosimilar pathway.
When does rivoglitazone lose exclusivity?
Rivoglitazone has no market exclusivity date because it has not received a U.S. marketing approval.
Historical compound, formulation, or method-of-use patents may have existed. Their commercial value depends on the specific patent family, jurisdiction, terminal disclaimers, patent-term adjustments, maintenance-fee payments, and ownership transfers. A historical patent filing does not establish current enforceability.
For a revived program, the relevant exclusivity analysis would include:
| Protection type | Current commercial implication |
|---|---|
| Composition-of-matter patent | Potentially expired or near expiration, depending on the earliest priority date |
| Formulation patent | Could protect a specific dosage form but would not necessarily block alternative formulations |
| Method-of-use patent | Could cover a defined patient population, combination, or treatment regimen |
| Manufacturing patent | Could create process barriers but generally would not prevent all alternative synthesis routes |
| Regulatory exclusivity | None identified because no approval exists |
| Orphan-drug exclusivity | No public evidence of an orphan designation |
| Pediatric exclusivity | None identified |
A complete patent-expiration analysis requires a verified patent-family review in the relevant jurisdictions. Public drug-status information alone does not support a reliable expiration-date conclusion.
What formulations and methods of use could be protected?
Rivoglitazone was developed primarily as an oral antidiabetic agent. The likely commercial dosage form was an oral tablet or equivalent solid dosage form.
Potential protection categories include:
- Rivoglitazone composition-of-matter claims.
- Pharmaceutical compositions containing rivoglitazone and excipients.
- Immediate-release oral tablets.
- Modified-release or controlled-release formulations.
- Dose-ranging regimens for type 2 diabetes.
- Use in patients with inadequate glycemic control on metformin or other antidiabetic agents.
- Combination treatment with metformin, sulfonylureas, insulin, or other glucose-lowering medicines.
- Treatment of insulin resistance or related metabolic disorders.
These categories should not be treated as confirmed live rights without a patent-family search. No Orange Book-listed formulation or method-of-use patent can currently be used to establish market exclusivity because there is no approved rivoglitazone product.
What patent litigation and Paragraph IV risks affect rivoglitazone?
There is no established U.S. Paragraph IV litigation framework for rivoglitazone because no approved reference product exists.
The principal legal risks would arise only after a sponsor revives the program:
- Preclinical or clinical investment could be exposed to weak composition claims.
- A new sponsor might need to operate around expired or narrow formulation patents.
- A later approval could face generic competition if no valid patents remain.
- Method-of-use claims might be difficult to enforce where physicians prescribe the drug for broad diabetes treatment.
- Prior art relating to PPAR-gamma agonists could limit patent scope.
- Historical ownership or license-chain issues could complicate enforcement.
No widely reported settlement agreement involving rivoglitazone and a generic manufacturer has established a commercial launch date. There is also no known authorized generic or licensed commercial partner with a current marketed product.
How strong is the rivoglitazone patent estate?
The commercial strength of the estate appears limited by the age of the program and the absence of an approved product.
A practical strength assessment is:
| Patent-estate factor | Assessment |
|---|---|
| Composition protection | Potentially weakened by age and prior-art exposure |
| Formulation protection | Could retain value if a new formulation solves a clinically relevant problem |
| Method-of-use protection | Likely narrower and more vulnerable to invalidity or noninfringement challenges |
| Manufacturing protection | May create process-specific advantages but not broad market exclusivity |
| Regulatory exclusivity | None |
| Litigation leverage | Low in the absence of an approved product |
| Licensing value | Mainly contingent on new clinical data or a differentiated formulation |
The strongest potential asset would be a patentable formulation or clinical use that materially improves the safety profile of PPAR-gamma therapy. A standard oral rivoglitazone tablet would have limited strategic value against low-cost generic pioglitazone.
How does rivoglitazone compare with pioglitazone and rosiglitazone?
Rivoglitazone entered a crowded drug class dominated by established products.
| Factor | Rivoglitazone | Pioglitazone | Rosiglitazone |
|---|---|---|---|
| Approval status | Not approved | Approved in major markets | Approved with significant restrictions in some markets |
| Commercial availability | None | Generic and widely available | Limited relative to historical use |
| Mechanism | PPAR-gamma agonist | PPAR-gamma agonist | PPAR-gamma agonist |
| Main value proposition | Intended insulin sensitization | Low-cost, established efficacy | Glycemic efficacy with significant safety history |
| Patent position | No active product exclusivity identified | Broad historical patent estate largely expired | Broad historical patent estate largely expired |
| Competitive barrier | Lack of approval and differentiation | Generic price and clinical familiarity | Safety and regulatory restrictions |
| Re-entry case | Requires new differentiation | Incumbent comparator | Less attractive benchmark because of safety history |
Rivoglitazone would compete against generic pioglitazone, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, insulin, and newer combination therapies. The current diabetes market favors drugs with cardiovascular, renal, weight-loss, or hypoglycemia advantages. A conventional PPAR-gamma profile is commercially disadvantaged unless safety is substantially improved.
What is the projected market opportunity for rivoglitazone?
The near-term market projection is effectively zero because the drug is not approved or marketed.
A relaunch would require a new sponsor to fund toxicology, clinical pharmacology, dose selection, pivotal efficacy trials, long-term safety studies, regulatory submissions, and commercial infrastructure. The economic case would depend on a differentiated label.
Base case: no relaunch
Under the base case, rivoglitazone remains inactive and produces no product revenue. Historical development expenditure has no direct commercial recovery unless rights are sold or the compound is repurposed.
Upside case: niche relaunch
A niche opportunity could exist if rivoglitazone demonstrates:
- Lower edema and heart-failure risk than older thiazolidinediones.
- Less weight gain.
- A favorable lipid or hepatic profile.
- Utility in a defined insulin-resistant population.
- A combination benefit with metformin or another established therapy.
- A delivery system that improves adherence or tolerability.
Even in this scenario, the product would likely require specialty positioning rather than broad first-line use. Payers would compare its price with inexpensive generic pioglitazone and with branded cardiometabolic therapies that offer outcome benefits.
Downside case: clinical revival without differentiation
A renewed program that shows only conventional glucose lowering would face a weak return profile. Generic competition, safety monitoring, and the cost of cardiovascular-outcome evidence would materially constrain pricing and uptake.
What licensing or acquisition opportunity exists?
Rivoglitazone could have value as an option asset rather than as a near-term commercial product.
A potential transaction would likely require:
- Verification of worldwide patent ownership.
- Confirmation that compound and formulation rights remain assignable.
- Review of all historical clinical data.
- New preclinical safety work.
- A defined differentiation hypothesis.
- A staged license with development milestones rather than a large upfront payment.
The most credible partnering case would involve a company focused on metabolic disease, repurposing, or novel oral formulations. Large pharmaceutical companies are unlikely to prioritize the asset without clear evidence that it addresses a safety limitation of existing PPAR-gamma agonists.
What generic launch risks exist?
There is no current generic launch risk because there is no approved rivoglitazone reference product.
If a new product were approved, generic entry would depend on:
- The validity and remaining term of composition claims.
- FDA-listed formulation patents.
- Approved methods of use.
- Any regulatory exclusivity.
- Whether the label contains protected indications.
- The availability of a noninfringing manufacturing route.
An approval without durable patent protection would expose the product to rapid generic competition, particularly because the active ingredient belongs to an established and price-sensitive class.
Key Takeaways
- Rivoglitazone, or CS-011, is an investigational PPAR-gamma agonist for type 2 diabetes.
- Historical development reached clinical-stage testing but did not result in an identified FDA, EMA, or PMDA approval.
- The product has no current market revenue, Orange Book listing, approved generic pathway, or biosimilar relevance.
- Its principal commercial obstacle is class-level safety risk combined with intense competition from generic pioglitazone and newer cardiometabolic drugs.
- A conventional rivoglitazone tablet has limited relaunch value.
- The only credible upside case depends on a demonstrable safety, formulation, or patient-selection advantage.
- Patent value cannot be inferred from historical development alone and appears commercially constrained by the age of the program.
FAQs
Is rivoglitazone still in clinical trials?
No active commercial-stage development program is publicly established. Historical trials were conducted, but the available record does not support an ongoing registration program.
Who developed rivoglitazone?
Rivoglitazone, also known as CS-011, was historically associated with Daiichi Sankyo and predecessor organizations.
Can a generic company file an ANDA for rivoglitazone?
Not in the conventional manner because no FDA-approved rivoglitazone reference product has been identified. An ANDA requires an approved reference-listed drug.
Is rivoglitazone a GLP-1 drug or SGLT2 inhibitor?
No. Rivoglitazone is an oral thiazolidinedione and PPAR-gamma agonist that improves insulin sensitivity.
Could rivoglitazone be repurposed for obesity?
A repurposing program would face significant safety and commercial hurdles. PPAR-gamma agonists are associated with weight gain, which makes obesity treatment an unfavorable initial positioning unless a substantially different pharmacologic profile is demonstrated.
References
-
ClinicalTrials.gov. (n.d.). Study records for CS-011 and rivoglitazone in type 2 diabetes. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2023). Guidance for industry: Diabetes mellitus developing drugs and therapeutic biologics for treatment and prevention. https://www.fda.gov/
-
Daiichi Sankyo Co., Ltd. (n.d.). Historical corporate and research pipeline information. https://www.daiichisankyo.com/
More… ↓
